Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years' accumulated evidence from clinical trials
Expert Rev Neurother. 2021 Jun 7. doi: 10.1080/14737175.2021.1935879. Online ahead of print.ABSTRACTINTRODUCTION: : Nabiximols, a cannabinoid-based oromucosal spray, is indicated as add-on therapy for symptomatic relief of spasticity in persons with multiple sclerosis (MS). This review compiles tolerability and safety data from clinical trials that investigated nabiximols for spasticity and/or chronic pain.AREAS COVERED: : Systematic searches identified 38 placebo-controlled randomised controlled trials (RCTs) or post-RCT open-label studies reporting safety data: 15 in (mainly MS) spasticity; 16 in neuropathic pain; six in...
Source: Expert Review of Neurotherapeutics - June 7, 2021 Category: Neurology Authors: Jos é María Prieto González Carlos Vila Silv án Source Type: research

Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence
Expert Rev Neurother. 2021 Jun 4:1-11. doi: 10.1080/14737175.2021.1935878. Online ahead of print.ABSTRACTINTRODUCTION: Vitamin D has long been known for its immune-modulating effects, next to its function in calcium metabolism. As a consequence, poor vitamin D status has been associated with many diseases including multiple sclerosis (MS). Epidemiological studies suggest an association between a poor vitamin D status and development of MS and a poor vitamin D status is associated with more relapses and faster progression after patients are diagnosed with MS.AREA’S COVERED: The aim of the authors was to review the rol...
Source: Expert Review of Neurotherapeutics - June 1, 2021 Category: Neurology Authors: Robin Boltjes Stephanie Knippenberg Oliver Gerlach Raymond Hupperts Jan Damoiseaux Source Type: research

Vitamin D supplementation in multiple sclerosis: An expert opinion based on the review of current evidence
Expert Rev Neurother. 2021 Jun 1. doi: 10.1080/14737175.2021.1935878. Online ahead of print.ABSTRACTINTRODUCTION: Vitamin D has long been known for its immune-modulating effects, next to its function in calcium metabolism. As a consequence, poor vitamin D status has been associated with many diseases including multiple sclerosis (MS). Epidemiological studies suggest an association between a poor vitamin D status and development of MS and a poor vitamin D status is associated with more relapses and faster progression after patients are diagnosed with MS.AREA’S COVERED: The aim of the authors was to review the role of ...
Source: Expert Review of Neurotherapeutics - June 1, 2021 Category: Neurology Authors: Robin Boltjes Stephanie Knippenberg Oliver Gerlach Raymond Hupperts Jan Damoiseaux Source Type: research

Outcomes measures in idiopathic intracranial hypertension
Expert Rev Neurother. 2021 Jun 7:1-14. doi: 10.1080/14737175.2021.1931127. Online ahead of print.ABSTRACTIntroduction: Idiopathic intracranial hypertension is a condition characterized by raised intracranial pressure, papilledema, and normal neuroimaging (aside from radiological signs of raised intracranial pressure). Symptoms of idiopathic intracranial hypertension include chronic headaches and for some, visual loss. New treatments are unmet clinical needs.Areas covered: The aim of this review is to present the evidence base and considered opinion on outcome measures to determine successful management of idiopathic intrac...
Source: Expert Review of Neurotherapeutics - May 28, 2021 Category: Neurology Authors: Susan P Mollan Alexandra J Sinclair Source Type: research

Outcomes measures in idiopathic intracranial hypertension
Expert Rev Neurother. 2021 May 28. doi: 10.1080/14737175.2021.1931127. Online ahead of print.ABSTRACTIntroductionIdiopathic Intracranial Hypertension is condition characterised by raised intracranial pressure, papilledema, and normal neuroimaging (aside from radiological signs of raised intracranial pressure). Symptoms of idiopathic intracranial hypertension include chronic headaches and for some, visual loss. New treatments are an unmet clinical need.Areas coveredThe aim of this review is to present the evidence base and considered opinion on outcome measures to determine successful management of idiopathic intracranial h...
Source: Expert Review of Neurotherapeutics - May 28, 2021 Category: Neurology Authors: Susan P Mollan Alexandra J Sinclair Source Type: research